{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:54:44Z","timestamp":1767848084101,"version":"3.49.0"},"reference-count":10,"publisher":"JLE","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Dermatol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1684\/ejd.2019.3499","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:17:48Z","timestamp":1696864668000},"page":"213-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab"],"prefix":"10.1684","volume":"29","author":[{"given":"Roberto","family":"Maglie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Antiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavinia","family":"Quintarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Verdelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"key":"3499_CR1","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","volume":"78","author":"KT Amber","year":"2018","unstructured":"Amber KT, Maglie R, Solimani F, Eming R, Hertl M. Targeted therapies for autoimmune bullous diseases: current status. Drugs 2018; 78: 1527\u201348.","journal-title":"Drugs"},{"key":"3499_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1346-8138.2009.00639.x","volume":"36","author":"MJ Kim","year":"2009","unstructured":"Kim MJ, Kim HO, Kim HY, Park YM. Rituximab-induced vasculitis: a case report and review of the medical published work. J Dermatol 2009; 36: 284\u20137.","journal-title":"J Dermatol"},{"key":"3499_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2230.2005.01941.x","volume":"31","author":"AS Belgi","year":"2006","unstructured":"Belgi AS, Azeez M, Hoyle C, Williams RE. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 2006; 31: 143.","journal-title":"Clin Exp Dermatol"},{"key":"3499_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","volume":"68","author":"YA Leshem","year":"2013","unstructured":"Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 Patients. J Am Acad Dermatol 2013; 68: 404\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"3499_CR5","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bjd.13823","volume":"173","author":"RJ Feldman","year":"2015","unstructured":"Feldman RJ. Paradoxical worsening of pemphigus vulgaris following rituximab therapy. Br J Dermatol 2015; 173: 858\u20139.","journal-title":"Br J Dermatol"},{"key":"3499_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0378-6323.174379","volume":"82","author":"VK Sharma","year":"2016","unstructured":"Sharma VK, Bhari N, Gupta S, et al. Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study. Indian J Dermatol Venereol Leprol 2016; 82: 389\u201394.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"3499_CR7","volume-title":"Am J Clin Dermatol","author":"N Kremer","year":"2018","unstructured":"Kremer N, Snast I, Cohen ES, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol 2018, Ahead of print. doi: 10.1007\/s40257-018-0401-6."},{"key":"3499_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000452828","volume":"9","author":"A Bilgi\u00e7 Temel","year":"2017","unstructured":"Bilgi\u00e7 Temel A, Bassorgun CI, Akman-Karakas, A, Alpsoy E, Uzun S. Successful treatment of a bullous pemphigoid patient with rituximab who was refractory to corticosteroid and omalizumab treatments. Case Rep Dermatol 2017; 9: 38\u201344.","journal-title":"Case Rep Dermatol"},{"key":"3499_CR9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1684\/ejd.2018.3366","volume":"28","author":"E Cozzani","year":"2018","unstructured":"Cozzani E, Gasparini G, Di Zenzo G, Parodi A. Immunoglobulin E and bullous pemphigoid. Eur J Dermatol 2018; 28: 440\u20138.","journal-title":"Eur J Dermatol"},{"key":"3499_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","volume":"153","author":"N van Beek","year":"2017","unstructured":"van Beek N, L\u00fcttmann N, Huebner F, et al. Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol 2017; 153: 30\u20138.","journal-title":"JAMA Dermatol"}],"container-title":["European Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2019.3499.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ejd.2019.3499\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2019.3499.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2019.3499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:21:33Z","timestamp":1741191693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2019.3499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3499"],"URL":"https:\/\/doi.org\/10.1684\/ejd.2019.3499","relation":{},"ISSN":["1952-4013"],"issn-type":[{"value":"1952-4013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"27 Mai 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}